In the second 6 months of the study, people who kept taking tesamorelin reduced their visceral fat by nearly 18%, while those who stopped regained the fat quickly, showing a clear cause-and-effect relationship.

Pro

Against

Evidence from Studies

Supporting (3)

Community contributions welcome

Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension

Randomized Controlled Trial

Human

2010 Mar

The study found that taking tesamorelin for a year shrunk belly fat by about 18%, but when people stopped taking it, the fat came right back—proving the drug directly causes the fat loss and it’s not permanent without continued use.

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Randomized Controlled Trial

Human

2010 Sep

This study shows that tesamorelin not only reduces belly fat in HIV patients but also keeps it reduced as long as the treatment is continued.

Tesamorelin for the treatment of excess abdominal fat in HIV-1-infected patients with lipodystrophy

Case-Control Study

Human

2011 Jan

This study confirms that tesamorelin works to reduce belly fat in HIV patients and that the effect stops when the treatment is stopped.

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Similar Assertions

Administration of tesamorelin results in a statistically significant reduction in visceral adipose tissue volume compared to placebo, with a mean reduction of approximately 11% after 6 months of treatment.

89%

In a 6-month randomized, placebo-controlled trial, tesamorelin significantly reduced both visceral and hepatic (liver) fat, with liver fat reduction being particularly important as it improves insulin sensitivity and glucose metabolism.

81%

A daily injection called tesamorelin helps HIV patients on medication lose belly fat inside their abdomen, while a fake shot doesn’t.

80%

If HIV patients keep taking tesamorelin for a full year, their dangerous belly fat drops by about 18% compared to when they started — but we don’t know how much better that is than just stopping the drug, because the placebo group didn’t stay on it for a year.

78%

Tesamorelin independently increases fat density in visceral and subcutaneous adipose tissue, indicating improved fat quality with smaller adipocytes, better vascularization, reduced hypoxia, and decreased inflammation, independent of fat quantity changes.

78%